Pulmonary Hypertension (PH) associated with Interstitial Lung Disease (ILD)
TECXTectonic TherapeuticCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for TX45 in Pulmonary Hypertension (PH) associated with Interstitial Lung Disease (ILD). The expected timing is based on the latest available company guidance and may change.
8/7/25- Initiate trial in 2026. 02/26/26:- Phase 2 PH-ILD trial initiated; first site opened for screening in February 2026. Phase 2 readout timing TBA. 05/07/26:- ALPINE Ph2 PH-ILD trial open-label, 16-week, up to 25 patients; primary endpoint PVR change. 08/06/26:- Phase 2 PH-ILD readout funding reiterated; timing remains TBA.
Verification
Confirm timing and program details against the company announcement or filing.